𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Oral idarubicin in the treatment of acute myelogenous leukaemia and the blast phase of chronic myeloid leukaemia

✍ Scribed by S. T. A. Malik; J. Tucker; A. Z. S. Rohatiner; W. Brace; T. A. Lister

Publisher
John Wiley and Sons
Year
1989
Tongue
English
Weight
307 KB
Volume
7
Category
Article
ISSN
0278-0232

No coin nor oath required. For personal study only.

✦ Synopsis

Fourteen patients with poor-risk acute myelogenous leukaemia (AML) and five patients with accelerated phase/blast crisis chronic myeloid leukaemia (CML) were treated with 3 days of oral idarubicin (25 mg/m2/ day). No complete remissions or return to chronic phase CML were observed. A fall in the peripheral blast count was seen in all patients with the first cycle of treatment, and with subsequent cycles in CML patients, but all responses were transient, with eventual reemergence of peripheral blasts. In some patients, there was a clear cut improvement in symptoms such as bone and splenic pain. Five of the AML patients and all of the CML patients were treated as out-patients. In this group of patients oral idarubicin was found to be a useful drug for palliative treatment.

πŸ“œ SIMILAR VOLUMES

Clofarabine in the treatment of poor ris
Clofarabine in the treatment of poor risk acute myeloid leukaemia
✍ Janusz Krawczyk; Naeem Ansar; Ronan Swords; Tracy Murphy; Barry MacDonagh; Teres πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 92 KB

## Abstract Clofarabine is a second generation nucleoside analogue. It inhibits DNA repair and activates the mitochondrial apoptotic pathway leading to cell death. __In vitro__ clofarabine has demonstrated synergy with daunorubicin and Ara‐C and in phase II clinical trials has shown promising activ

Hepatotoxicity in the treatment of acute
Hepatotoxicity in the treatment of acute lymphoblastic leukaemia
✍ Topley, J. M. ;Benson, J. ;Squier, M. V. ;Chessells, J. M. πŸ“‚ Article πŸ“… 1979 πŸ› John Wiley and Sons 🌐 English βš– 368 KB

Serial liver function tests and percutaneous liver biopsies were performed on 21 children receiving treatment for acute lymphoblastic leukaemia (ALL). The patients received continuing chemotherapy either with daily 6-mercaptopurine and weekly methotrexate or with five-day pulses of these drugs every

Therapy adapted to molecular response in
Therapy adapted to molecular response in patients with chronic myelogenous leukaemia in first chronic phase: results of the Duesseldorf study
✍ Frank Neumann; Judith Markett; Roland Fenk; Monika Pooten; Anne Koch; Daniela Br πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 118 KB

## Abstract This study evaluates response‐adapted treatment of chronic myelogenous leukaemia (CML) in chronic phase using molecular response criteria. __bcr‐abl__/G6PDH ratios were assessed by Light‐Cycler quantitative real‐time polymerase chain reaction (PCR( in 277 peripheral blood samples from 3

The role of MDR-related proteins in the
The role of MDR-related proteins in the prognosis of adult acute myeloid leukaemia (AML) with normal karyotype
✍ Daniela Damiani; Mario Tiribelli; Donatella Raspadori; Angela Michelutti; Alessa πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 164 KB

## Abstract Cytogenetic abnormalities are among the most important factors affecting the outcome of patients with acute myeloid leukaemia (AML), but approximately 40–50% of AML cases display a normal karyotype at diagnosis. Multidrug resistance (MDR) proteins overexpression is associated with worse